Finally, enasidenib has been evaluated as maintenance therapy for high-risk MDS and AML-MRC patients with IDH2 mutation with overall, progression-free and relapse rates being 74%, 69% and 16%, respectively, and relatively rare severe adverse effects [183]. This evidence concerns the gene IDH2 and acute myeloid leukemia.